Annals of Hematology

, Volume 98, Issue 5, pp 1169–1176 | Cite as

Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ?

  • Dai ChiharaEmail author
  • Yasuhiro Oki
  • Michelle A. Fanale
  • Jason R. Westin
  • Loretta J. Nastoupil
  • Sattva Neelapu
  • Luis Fayad
  • Nathan H. Fowler
  • Chan Yoon Cheah
Original Article


Stage I non-Hodgkin lymphoma (NHL) is rare; prognostic impact of different histologic subtypes and treatment modality is still unclear. We used the Surveillance, Epidemiology and End Results (SEER) database to evaluate survival outcomes among adult patients (age ≥ 18 years, N = 58,230) diagnosed with stage I NHL of various histologic subtypes between 1998 and 2014. Five-year disease-specific survival of patients with stage I diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), small lymphocytic lymphoma (SLL), Burkitt lymphoma (BL), mantle cell lymphoma (MCL), and peripheral T cell lymphoma (PTCL) was 82%, 92%, 95%, 89%, 78%, 77%, and 77%, respectively. The median disease-specific survival was not reached in all histologic subtypes analyzed; however, there does not appear to be a plateau in disease-specific survival of patients with stage I NHL irrespective of subtypes. Although lymphoma was the most common cause of death (40.7%), death from other cancer (17.4%) and cardiovascular disease (13.6%) were also frequent. Chemotherapy appeared favorably associated with OS in patients with DLBCL, BL, and MCL while patients with FL, MZL, SLL, and PTCL who require chemotherapy for initial treatment showed shorter OS. Patients with stage I NHL have favorable disease-specific survival; however, no plateau was seen regardless of histologic subtypes thus suggesting that patients may need attention and follow-up even in aggressive lymphomas after 5 years of remission.


Stage I lymphoma Disease-specific survival SEER Radiation 


Compliance with ethical standards

Conflict of interest

Dr Fanale reports grants and personal consulting fees through 06/04/18 from Seattle Genetics and salary and stocks from 10/01/18 following the start of her employment with Seattle Genetics. Grants and personal fees from Takeda through 06/04/18, grants and personal fees from Celgene through 06/04/18, grants from ADC Therapeutics through 06/04/18, grants and personal fees from BMS through 06/04/18, grants and personal fees from Merck through 06/04/18, grants from Molecular Templates through 06/04/18, personal fees from Bayer through 06/04/18, personal fees from Spectrum through 06/04/18, grants from MedImmune through 06/04/18, grants from Gilead through 06/04/18, and grants from Genentech through 06/04/18.

Ethical approval

SEER data is publically available de-identified database and thus deemed not needing approval from institutional review board.

Supplementary material

277_2018_3571_Fig3_ESM.png (1023 kb)

(PNG 1022 kb)

277_2018_3571_MOESM1_ESM.tif (264 kb)
High Resolution Image (TIF 264 kb)


  1. 1.
    Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, Vanderplas A, Zelenetz AD, Abel GA, Rodriguez MA, Nademanee A, Kaminski MS, Czuczman MS, Millenson M, Niland J, Gascoyne RD, Connors JM, Friedberg JW, Winter JN (2014) An enhanced international prognostic index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 123(6):837–842. CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, LeBlanc M, Carlin S, Chase E, Fisher RI (1998) Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 339(1):21–26. CrossRefPubMedGoogle Scholar
  3. 3.
    Shenkier TN, Voss N, Fairey R, Gascoyne RD, Hoskins P, Klasa R, Klimo P, O'Reilly SE, Sutcliffe S, Connors JM (2002) Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. J Clin Oncol 20(1):197–204. CrossRefPubMedGoogle Scholar
  4. 4.
    Stephens DM, Li H, LeBlanc ML, Puvvada SD, Persky D, Friedberg JW, Smith SM (2016) Continued risk of relapse independent of treatment modality in limited-stage diffuse large B-cell lymphoma: final and long-term analysis of southwest oncology group study S8736. J Clin Oncol 34(25):2997–3004. CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    National Comprehensive Cancer Network. (2018) B-cell lymphomas (version 5.2018).
  6. 6.
    Yamaguchi M, Suzuki R, Oguchi M (2018) Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type. Blood 131:2528–2540. CrossRefPubMedGoogle Scholar
  7. 7.
    Grommes C, DeAngelis LM (2017) Primary CNS lymphoma. J Clin Oncol 35(21):2410–2418. CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Dunleavy K (2017) Primary mediastinal B-cell lymphoma: biology and evolving therapeutic strategies. Hematology Am Soc Hematol Educ Program 2017(1):298–303. CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Cheah CY, Wirth A, Seymour JF (2014) Primary testicular lymphoma. Blood 123(4):486–493. CrossRefGoogle Scholar
  10. 10.
    Chihara D, Oki Y, Fanale MA, Westin JR, Nastoupil LJ, Neelapu S, Fayad L, Fowler NH, Cheah CY (2018) Stage I non-Hodgkin lymphoma: difference in survival outcome by primary extranodal site of involvement. Br J Haematol doi:
  11. 11.
    Suzuki R, Chihara D, Asano N, Ohmachi K, Kinoshita T, Matsue K, Suzumiya J, Ogura M (2016) Limited-stage mantle cell lymphoma. Blood 128(22):5330–5330Google Scholar
  12. 12.
    Romaguera JE, Medeiros LJ, Hagemeister FB, Fayad LE, Rodriguez MA, Pro B, Younes A, McLaughlin P, Goy A, Sarris AH, Dang NH, Samaniego F, Brown HM, Gagneja HK, Cabanillas F (2003) Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer 97(3):586–591. CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Phan J, Mazloom A, Medeiros LJ, Zreik TG, Wogan C, Shihadeh F, Rodriguez MA, Fayad L, Fowler N, Reed V, Horace P, Dabaja BS (2010) Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol 28(27):4170–4176. CrossRefPubMedGoogle Scholar
  14. 14.
    Lamy T, Damaj G, Soubeyran P, Gyan E, Cartron G, Bouabdallah K, Gressin R, Cornillon J, Banos A, Le Du K, Benchalal M, Moles MP, Le Gouill S, Fleury J, Godmer P, Maisonneuve H, Deconinck E, Houot R, Laribi K, Marolleau JP, Tournilhac O, Branger B, Devillers A, Vuilliez JP, Fest T, Colombat P, Costes V, Szablewski V, Bene MC, Delwail V (2017) R-CHOP 14 with or without radiotherapy in non-bulky limited-stage diffuse large B-cell lymphoma (DLBCL). Blood 131:174–181. CrossRefPubMedGoogle Scholar
  15. 15.
    Shah GD, Yahalom J, Correa DD, Lai RK, Raizer JJ, Schiff D, LaRocca R, Grant B, DeAngelis LM, Abrey LE (2007) Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 25(30):4730–4735. CrossRefPubMedGoogle Scholar
  16. 16.
    Vitolo U, Chiappella A, Ferreri AJ, Martelli M, Baldi I, Balzarotti M, Bottelli C, Conconi A, Gomez H, Lopez-Guillermo A, Martinelli G, Merli F, Novero D, Orsucci L, Pavone V, Ricardi U, Storti S, Gospodarowicz MK, Cavalli F, Sarris AH, Zucca E (2011) First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Clin Oncol 29(20):2766–2772. CrossRefPubMedGoogle Scholar
  17. 17.
    Reagan PM, Friedberg JW (2015) Follicular lymphoma: first-line treatment without chemotherapy for follicular lymphoma. Curr Treat Options in Oncol 16(7):32. CrossRefGoogle Scholar
  18. 18.
    Macmanus MP, Fisher R, Roos D, O'Brien P, Macann A, Tsang R, Davis S, Christie D, McClure B, Joseph D, Seymour JF (2017) CVP or R-CVP given after involved-field radiotherapy improves progression free survival in stage I–II follicular lymphoma: results of an international randomized trial. Hematol Oncol 35:31–31. CrossRefGoogle Scholar
  19. 19.
    Clarke CA, Undurraga DM, Harasty PJ, Glaser SL, Morton LM, Holly EA (2006) Changes in cancer registry coding for lymphoma subtypes: reliability over time and relevance for surveillance and study. Cancer Epidemiol Biomark Prev 15(4):630–638. CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Dai Chihara
    • 1
    Email author
  • Yasuhiro Oki
    • 2
  • Michelle A. Fanale
    • 2
    • 3
  • Jason R. Westin
    • 2
  • Loretta J. Nastoupil
    • 2
  • Sattva Neelapu
    • 2
  • Luis Fayad
    • 2
  • Nathan H. Fowler
    • 2
  • Chan Yoon Cheah
    • 4
    • 5
    • 6
  1. 1.Department of Internal MedicineUniversity of New MexicoAlbuquerqueUSA
  2. 2.Department of Lymphoma/MyelomaThe University of Texas MD Anderson Cancer CenterHoustonUSA
  3. 3.Seattle GeneticsBothellUSA
  4. 4.Department of HaematologySir Charles Gairdner HospitalNedlandsAustralia
  5. 5.Department of HaematologyPathwest Laboratory MedicineNedlandsAustralia
  6. 6.Medical SchoolUniversity of Western AustraliaCrawleyAustralia

Personalised recommendations